Bio Pharma Dive
JUNE 26, 2021
Results published in The New England Journal of Medicine offer the first clinical evidence that CRISPR gene editing inside the body can be safe and effective, a culmination of years of scientific research.
World of DTC Marketing
JULY 1, 2021
SUMMARY: Online health seeker numbers are still very high, indicating that people are doing their research first before asking for a prescription drug. Online health seekers trust pharma products but find product websites hard to read and inconsistent with their needs. Telehealth numbers are dropping rapidly, but people still want to use telehealth to ask for Rx renewals and ask general questions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
JUNE 29, 2021
Company initially withdrew a marketing authorisation application for the gene therapy last year
BioPharma Reporter
JUNE 28, 2021
Live biotherapeutic product (LBP) developer, 4D Pharma, says it is building a âstrong body of evidenceâ for its portfolio of bacterial strains in relation to cancer, asthma, and neurodegenerative diseases, while the company also calls its recent dual listing a âtransformational milestoneâ.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
JULY 2, 2021
The agency is under pressure to grant full approvals to two coronavirus vaccines and faces important questions on how to handle the next Alzheimer's drugs after Aduhelm. A safety review of several arthritis medicines, meanwhile, is ongoing.
World of DTC Marketing
JUNE 28, 2021
SUMMARY: The debate around Biogen’s Alzheimer’s drug continues to rage. The clinical evidence supporting the approval of the drug is at best “weak.” How could the FDA approve a drug with such poor clinical data? How can Biogen’s employees continue to work for a company that is raping taxpayers for a drug that doesn’t work?
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
JUNE 29, 2021
Robert Galarza outlines how blockchain technology can be utilised to verify, validate and standardise the efficacy of medical cannabis and other plant based therapies in clinical trials. . The Chinese surgeon Huo Tuo first mixed powdered cannabis with wine to make an anesthetic sometime between 140 and 208 CE. Indeed, the Chinese term for “anesthesia” (mázui ??
Bio Pharma Dive
JUNE 28, 2021
A study of Gilead's Yescarta found the cell therapy dramatically outperformed chemotherapy and stem cell transplant in treating lymphoma, a result that could support much broader use of the drug.
World of DTC Marketing
JUNE 27, 2021
SUMMARY: According to the NEJM “in participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight” In the clinical study, participants were enrolled in an “intensive” behavioral study with 8 weeks low-calorie diet.
Pharma Times
JUNE 29, 2021
Mixing different vaccines produces a strong immune response against virus, according to researchers
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
BioSpace
JUNE 29, 2021
Innate Pharma has an alternative to T cell-based immunotherapy that has the potential to quickly and safely eradicate solid and metastatic tumors in the body.
Bio Pharma Dive
JULY 1, 2021
A five-year alliance with high-profile biotech ElevateBio is designed to get around a bottleneck that has held back the institution’s gene therapy work.
World of DTC Marketing
JULY 2, 2021
SUMMARY: Leadership is the ability to influence or guide others. Too many pharma CEOs are bad leaders because they fear failure, losing power, and focus too much on metrics not important to the rank and file. Six out of 10 employees said they feel demotivated by their CEOs; 70% say CEO pay was too high in general. The median CEO of the drug companies outpaced the more modest pay gains of their employees.
Pharma Times
JUNE 29, 2021
Sanofi is currently collaborating with Translate Bio on a mRNA-based COVID-19 vaccine candidate
pharmaphorum
JUNE 29, 2021
Giving one dose each of AstraZeneca and Pfizer COVID-19 vaccines provides good protection against the SARS-CoV-2 virus, but may be associated with more adverse reactions, according to new clinical trial data. The Com-COV trial compared two shots with Pfizer/BioNTech’s Comirnaty, two doses of AstraZeneca’s Vaxzevria, and a mixed regimen of one of each jab, and found that all were effective at stimulating a “robust” immune response against the coronavirus, according to the
Bio Pharma Dive
JUNE 30, 2021
The companies aim to develop therapies for complement-driven diseases, a specialty of Apellis and relatively new research ground for gene editing.
World of DTC Marketing
JUNE 30, 2021
SUMMARY: The pharmaceutical trade publications, except STAT News and Endpoints, have remained silent on the sham approval of Biogen’s Alzheimer’s drug. Pharma trade magazines have become irrelevant, and most could care less what they print, although they try to suck up with phony awards. It’s up to people within the industry to push back and try to be the change we want and need to see.
Pharma Times
JUNE 29, 2021
The new Code has been updated to reflect changes in the pharma environment
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
NY Times
JULY 1, 2021
The Pfizer and Moderna vaccines are safe and effective. Full approval from the F.D.A. will help stop the spread of Covid-19.
Bio Pharma Dive
JUNE 28, 2021
The agency's decision-making process as well as Biogen's pricing of Aduhelm at $56,000 per year are both under the microscope as the repercussions of the controversial OK continue to be felt.
BioSpace
JUNE 28, 2021
Tofersen is the furthest along of four ASOs currently in clinical development for ALS and as such, there is quite a bit riding on the results of the VALOR trial which has an estimated completion date of August 31st, 2021.
Pharma Times
JULY 2, 2021
AZD4831 is being investigated in patients with heart failure with preserved ejection fraction (HFpEF)
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
XTalks
JULY 2, 2021
There have been growing reports of women experiencing changes in their menstrual cycle after receiving a shot of a COVID-19 vaccine. Some women have said they got their periods early following vaccination, or that their periods were unusually heavy and/or painful. There have also been reports of post-menopausal women and trans men experiencing bleeding or spotting after getting the shot.
Bio Pharma Dive
JUNE 28, 2021
Wearables can minimize trips to clinic sites and may provide study participants and cancer patients with a feeling of having more control over how they manage their own illness.
pharmaphorum
JUNE 28, 2021
Renal diseases represent a formidable challenge on public health systems around the world. They are costly in terms of economic burden and quality of life, especially among older patient populations, and are closely linked to other chronic conditions such as cardiovascular disease and diabetes. Joan Perelló and Adam Levy explore the advancement of treatments in the renal space.
Pharma Times
JULY 2, 2021
Rylaze has been specifically developed for patients who have developed hypersensitivity to E.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
XTalks
JULY 1, 2021
The safety of titanium dioxide in food, an additive found in thousands of ultra-processed foods, is now being questioned by the European Food Safety Authority (EFSA) after an in-house study conducted in March. In a surprising twist, the study concluded that the agency no longer considers titanium dioxide a safe food additive. So what does this mean?
Bio Pharma Dive
JUNE 29, 2021
Cerevel Therapeutics on Tuesday revealed positive results from an early-stage study of one of its drugs, doubling the price of the company's stock.
pharmaphorum
JUNE 28, 2021
The first ever clinical data with a CRISPR/Cas9 drug used to edit the genomes of cells within the body has yielded impressive results in patients with ATTR amyloidosis, a life-threatening rare disease. . Preliminary results from a phase 1 trial run by Regeneron and CRISPR specialist Intellia Therapeutics – co-founded by Nobel Prize winner Jennifer Doudna – showed steep reductions in a biomarker of ATTR amyloidosis disease activity with a single dose of the NTLA-2001 drug.
Pharma Times
JULY 1, 2021
Data also shows pharma companies worked with fewer HCPS and HCOs in 2020 compared to 2019
Expert insights. Personalized for you.
363 
Let's personalize your content